• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Trans R Soc Trop Med Hyg . The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroep

tetano

Editor, Senior Moderator
Trans R Soc Trop Med Hyg


. 2021 Aug 2;trab109.
doi: 10.1093/trstmh/trab109. Online ahead of print.
The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study


Nandini Sharma[SUP] 1 [/SUP], Pragya Sharma[SUP] 1 [/SUP], Saurav Basu[SUP] 1 [/SUP], Sonal Saxena[SUP] 2 [/SUP], Rohit Chawla[SUP] 2 [/SUP], Kumar Dushyant[SUP] 1 [/SUP], Nutan Mundeja[SUP] 3 [/SUP], Zeasaly Marak[SUP] 4 [/SUP], Sanjay Singh[SUP] 5 [/SUP], Gautam Singh[SUP] 6 [/SUP], Ruchir Rustagi[SUP] 5 [/SUP]



Affiliations

Abstract

Background: Three rounds of a repeated cross-sectional serosurvey to estimate the change in seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were conducted from August to October 2020 in the state of Delhi, India, in the general population ≥5 y of age.
Methods: The selection of participants was through a multistage sampling design from all 11 districts and 280 wards of the city-state, with multistage allocation proportional to population size. The blood samples were screened using immunoglobulin G (IgG) enzyme-linked immunosorbent assay kits.
Results: We observed a total of 4267 (N=150 46), 4311 (N=17 409) and 3829 (N=15 015) positive tests indicative of the presence of IgG antibody to SARS-CoV-2 during the August, September and October 2020 serosurvey rounds, respectively. The adjusted seroprevalence declined from 28.39% (95% confidence interval [CI] 27.65 to 29.14) in August to 24.08% (95% CI 23.43 to 24.74) in September and 24.71% (95% CI 24.01 to 25.42) in October. On adjusted analysis, participants with lower per capita income, living in slums or overcrowded households and those with diabetes comorbidity had significantly higher statistical odds of having antibody positivity (p<0.01).
Conclusions: Nearly one in four residents in Delhi, India ≥5 y of age had the SARS-CoV-2 infection during August-October 2020.

Keywords: COVID-19; SARS-CoV-2; serosurvey.
 
Back
Top Bottom